Neuvenge
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development (clinical trial) by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Neuvenge
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development (clinical trial) by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.
has abstract
Neuvenge, Lapuleucel-T (APC 80 ...... ed on bladder cancer patients.
@en
Wikipage page ID
30,045,028
page length (characters) of wiki page
Wikipage revision ID
955,786,546
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
subject
hypernym
type
comment
Neuvenge, Lapuleucel-T (APC 80 ...... ed on bladder cancer patients.
@en
label
Neuvenge
@en